Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2
Copyright © 2023. Published by Elsevier Ltd..
COVID-19 is a severe respiratory illness that has emerged as a devasting health problem worldwide. The disease outcome is heterogeneous, which is most likely dependent on the immunity of an individual. Asymptomatic and mildly/moderate symptomatic (non-severe) patients likely develop an effective early immune response and clear the virus. However, severe symptoms dominate due to a failure in the generation of an effective and specific early immune response against SARS-CoV-2. Moreover, a late surge in pathogenic inflammation involves dysregulated innate and adaptive immune responses leading to local and systemic tissue damage and the emergence of severe disease symptoms. In this review, we describe the potential mechanisms of protective and pathogenic immune responses in "mild/moderate" and "severe" symptomatic SARS-CoV-2 infected people, respectively, and discuss the immune components that are currently targeted for therapeutic intervention.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:156 |
|---|---|
| Enthalten in: |
Molecular immunology - 156(2023) vom: 17. Apr., Seite 111-126 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Purbey, Prabhat K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptive immunity |
|---|
| Anmerkungen: |
Date Completed 31.03.2023 Date Revised 12.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.molimm.2023.03.009 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM354270168 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM354270168 | ||
| 003 | DE-627 | ||
| 005 | 20240313233345.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.molimm.2023.03.009 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1326.xml |
| 035 | |a (DE-627)NLM354270168 | ||
| 035 | |a (NLM)36921486 | ||
| 035 | |a (PII)S0161-5890(23)00052-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Purbey, Prabhat K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.03.2023 | ||
| 500 | |a Date Revised 12.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Ltd. | ||
| 520 | |a COVID-19 is a severe respiratory illness that has emerged as a devasting health problem worldwide. The disease outcome is heterogeneous, which is most likely dependent on the immunity of an individual. Asymptomatic and mildly/moderate symptomatic (non-severe) patients likely develop an effective early immune response and clear the virus. However, severe symptoms dominate due to a failure in the generation of an effective and specific early immune response against SARS-CoV-2. Moreover, a late surge in pathogenic inflammation involves dysregulated innate and adaptive immune responses leading to local and systemic tissue damage and the emergence of severe disease symptoms. In this review, we describe the potential mechanisms of protective and pathogenic immune responses in "mild/moderate" and "severe" symptomatic SARS-CoV-2 infected people, respectively, and discuss the immune components that are currently targeted for therapeutic intervention | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adaptive immunity | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Innate immunity | |
| 650 | 4 | |a Mild/ moderate | |
| 650 | 4 | |a Protective and pathogenic immune response | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a Severe | |
| 650 | 4 | |a Therapeutics | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 700 | 1 | |a Roy, Koushik |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Paul, Manash K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molecular immunology |d 1984 |g 156(2023) vom: 17. Apr., Seite 111-126 |w (DE-627)NLM000411434 |x 1872-9142 |7 nnns |
| 773 | 1 | 8 | |g volume:156 |g year:2023 |g day:17 |g month:04 |g pages:111-126 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.molimm.2023.03.009 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 156 |j 2023 |b 17 |c 04 |h 111-126 | ||